Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspectiveStephen Chaplin, Edward Li, Joris van Stiphout et al.|Journal of Managed Care & Specialty Pharmacy|2024Cited by 5
A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology populationJeanine Flanigan, G.H. Lyman, Joris van Stiphout et al.|Journal of Medical Economics|2025Cited by 1
133 Cost-effectiveness of dry-powder mannitol for inhalation as an add-on to best supportive care (BSC) in the treatment of adult cystic fibrosis (CF) patients in IrelandMatthias Schwenkglenks, Joris van Stiphout, Toby J. Toward et al.|Journal of Cystic Fibrosis|2015Cited by 0